Kala Pharmaceuticals president/chief business officer steps down

Essential IR Insights Newsletter Fall - 2023

A Corporation Clearly Pinpoints Activist Investor Activity

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Kala Pharmaceuticals, Inc. said Charles McDermott stepped down as president and chief business officer on Aug. 7.

Mark Iwicki, who has been CEO and chairman of the company's board since September 2015, took over the additional role of president.

Iwicki previously served as CEO and president of biopharmaceutical company Civitas Therapeutics Inc.

McDermott's resignation was not due to any disagreement with Kala Pharmaceuticals.